Business
With Biogen’s multiple sclerosis portfolio facing more generic pressure than ever, the company is eyeing a busy late-stage pipeline and hunting for deals to build its return to growth.
FEATURED STORIES
Analysts parsed the limited data available for Pfizer’s obesity candidate on the pharma’s fourth-quarter earnings call Tuesday, looking for any nugget of additional context.
After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.
After suffering in the wake of expired tax incentives for pharmas, the island is trying to take advantage of geopolitics to grow its drug manufacturing sector.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Boston Biomedical announced it had launched an oncology research alliance with Columbia University, Harvard University and The Wistar Institute.
Owkin, which is developing Federated Learning and AI technologies to advance medical research, announces it is teaming up with technology company NVIDIA and King’s College London to deliver Federated Learning in the healthcare and life sciences sector.
Agreement strengthens collaboration between the companies following submission of the first dossier to the European Medicines Agency (EMA) for a CrisBio® produced recombinant vaccine
Columbia, SC – Obsidio, Inc., a pre-clinical stage medical materials developer pioneering a universal embolic hydrogel designed to be delivered minimally invasively through a clinical catheter for blood vessel occlusion, announced the formation of its clinical advisory board.
Utilizing AI technology to streamline information analysis and contribute to progress in an emergent, yet vital frontier of medical science
Vivoryon Therapeutics AG, announced its third quarter business update for the period ending September 30, 2019.
Here are five high-quality examples of major bio organizations’ efforts to showcase their commitment to providing a positive D&I work environment.
Under the terms of the deal with BBA, BBA acquired a capped 4.5% royalty on net sales of KSI-301 that will be paid upon marketing approval.
IFM Therapeutics is launching its third subsidiary this year with a focus on developing next-generation small molecule immunotherapies for inflammatory diseases and cancers.
SkinBioTherapeutics has announced its full year results and released details of its strengthened board and management team following the appointment of Stuart Ashman CEO.